Jon Congleton, Mineralys Therapeutics CEO

Af­ter hy­per­ten­sion com­peti­tor gets bought, Min­eralys lines up IPO plans

Min­eralys Ther­a­peu­tics has pen­ciled in a $100 mil­lion ini­tial pub­lic of­fer­ing to take its in­ves­ti­ga­tion­al hy­per­ten­sion drug in­to Phase III test­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.